Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RVMD 
Revolution Medicines Inc (RVMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: RVMD (3-star) is a STRONG-BUY. BUY since 46 days. Simulated Profits (49.21%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $77.58
1 Year Target Price $77.58
| 8 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 185.47% | Avg. Invested days 81 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.09B USD | Price to earnings Ratio - | 1Y Target Price 77.58 |
Price to earnings Ratio - | 1Y Target Price 77.58 | ||
Volume (30-day avg) 12 | Beta 0.99 | 52 Weeks Range 29.17 - 62.40 | Updated Date 11/5/2025 |
52 Weeks Range 29.17 - 62.40 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -1.39 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.47% | Return on Equity (TTM) -46.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6538462783 | Price to Sales(TTM) 9035.1 |
Enterprise Value 6538462783 | Price to Sales(TTM) 9035.1 | ||
Enterprise Value to Revenue 8370.02 | Enterprise Value to EBITDA -9.71 | Shares Outstanding 186933190 | Shares Floating 158526822 |
Shares Outstanding 186933190 | Shares Floating 158526822 | ||
Percent Insiders 1.99 | Percent Institutions 104.01 |
Upturn AI SWOT
Revolution Medicines Inc
Company Overview
History and Background
Revolution Medicines, Inc. was founded in 2014. It is a clinical-stage precision oncology company focused on developing novel therapies for RAS-addicted cancers.
Core Business Areas
- RAS(ON) Inhibitors: Focuses on developing direct RAS inhibitors, specifically targeting the active (ON) state of RAS proteins.
- RAS Companion Inhibitors: Developing inhibitors that work with RAS inhibition to enhance the therapeutic effect
Leadership and Structure
Mark A. Goldsmith, M.D., Ph.D. is the CEO. The company has a board of directors and a management team responsible for research, development, and commercialization strategies.
Top Products and Market Share
Key Offerings
- RMC-6236 (RAS(ON) Inhibitor): An oral RAS(ON) inhibitor targeting multiple RAS variants. It is currently in clinical trials for various cancers. Competitors include Mirati Therapeutics (MRTX) with Krazati and Amgen with Lumakras. Market share is emerging, and no revenue is realized as of November 2024.
- RMC-9805 (KRASG12D(ON) Inhibitor): A selective KRASG12D(ON) inhibitor also in clinical trials. Competitors include other companies developing KRASG12D inhibitors. Market share is emerging, and no revenue is realized as of November 2024.
Market Dynamics
Industry Overview
The precision oncology market is rapidly growing, driven by advancements in genomic sequencing and targeted therapies. RAS-targeted therapies are a significant area of interest due to the high prevalence of RAS mutations in cancer.
Positioning
Revolution Medicines is positioned as a leader in developing direct RAS(ON) inhibitors, a novel approach compared to other RAS-targeting strategies. Their competitive advantage lies in their specific targeting of the active state of RAS proteins.
Total Addressable Market (TAM)
The total addressable market for RAS-targeted therapies is estimated to be several billions of dollars annually. Revolution Medicines is positioned to capture a significant portion of this market with their innovative approach.
Upturn SWOT Analysis
Strengths
- Novel RAS(ON) inhibitor platform
- Strong preclinical data
- Experienced leadership team
- Potential for first-in-class therapies
Weaknesses
- Clinical trial risks
- High cash burn rate
- Dependence on single technology platform
- Limited commercialization experience
Opportunities
- Expansion into new cancer types
- Partnerships with pharmaceutical companies
- Advancements in diagnostic technologies
- Regulatory approvals for lead candidates
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- AMGN
- LLY
Competitive Landscape
Revolution Medicines' advantage lies in its RAS(ON) inhibitor approach, but it faces strong competition from established pharmaceutical companies with marketed RAS inhibitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by advancements in preclinical and clinical development programs.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential commercialization of lead candidates. Analyst estimates vary depending on clinical trial data.
Recent Initiatives: Recent initiatives include ongoing clinical trials for RMC-6236 and RMC-9805, as well as exploring additional indications for their RAS(ON) inhibitor platform.
Summary
Revolution Medicines is a promising clinical-stage company focusing on novel RAS-targeted therapies. Their innovative RAS(ON) inhibitor platform gives them a competitive edge, but clinical trial success is critical for future growth. The company faces competition from larger, established pharmaceutical companies and needs to manage its cash burn effectively. Its growth hinges on favorable clinical trial results and regulatory approvals, making it a higher-risk, higher-reward investment.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revolution Medicines Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-02-13 | CEO, President & Chairman Dr. Mark A. Goldsmith M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 700 | Website https://www.revmed.com |
Full time employees 700 | Website https://www.revmed.com | ||
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.